Pursuant to Iowa Code section 155A.46, the Board has developed, in collaboration with the Iowa Department of Health and Human Services, statewide protocols which authorize a pharmacist to:

  • Order and dispense an FDC-approved opioid antagonist to reverse opioid-related overdose,
  • Order and dispense nicotine-replacement tobacco cessation products,Ā 
  • Order and administer immunizations,
  • Initiate point-of-care testing and treatment of acute influenza, and
  • Initiate point-of-care testing and treatment of acute Group A streptococcal (GAS) pharyngitis.Ā 

The statewide protocols authorize the pharmacist to be the ordering practitioner under these protocols.

Back to top

Opioid Antagonists

  • Review the statewide protocol.
  • Download and print copies of theĀ eligibility assessment form.
  • Download and print copies of theĀ Iowa Naloxone Brochure.
  • Each participating pharmacist must complete at least one hour of continuing education related to opioid antagonist utilization.Ā  Each pharmacist must confirm completion of applicable continuing education by logging into theirĀ Online ProfileĀ and updating the information under Statewide Protocols.Ā 
  • Participating pharmacies must have policies and procedures (and train staff on the P&Ps) related to opioid antagonist dispensing under this statewide protocol.
Back to top

Opioid Antagonist (Naloxone) FAQs

Back to top

Nicotine-Replacement Tobacco Cessation

Back to top

Immunizations

  • Review the statewide protocol.
  • ReviewĀ CDC ACIP Immunization schedules.
  • Each participating pharmacist must complete an approved program on vaccine administration and complete training on basic life support for health care providers which includes hands-on training.Ā  Each pharmacist must confirm completion of applicable continuing education by logging into theirĀ Online ProfileĀ and updating the information under Statewide Protocols.Ā 
  • ā€‹Ensure the completion of at least one hour of continuing education during the renewal period in which the pharmacist is engaged in vaccine administration.
Back to top

Point-of-Care Test and Treat - Influenza

  • Review the statewide protocol.
  • ReviewĀ CDC Influenza Antiviral Medications: Summary for Clinicians.
  • Each participating pharmacist must complete education and training from an ACPE-accredited provider in point-of-care CLIA-waived testing techniques appropriate to the test to be used.
  • Individuals involved with patient specimen collection shall have documented hands-on training for specimen collection which includes infection control measures.
  • Ensure the completion of at least one hour of continuing education during the renewal period in which the pharmacist is engaged in test and treat for influenza.
Back to top

Point-of-Care Test and Treat - Strep A

Back to top

Point-of-Care Test and Treat - COVID 19

  • At this time, the Board has not approved a statewide protocol for testing for and treating COVID-19.
  • Federal HHS recently issued a 9th Amendment to its PREP Act Declaration in which it authorizes pharmacists to order and administer COVID-19 therapeutics which are:
    • Authorized or approved by FDA and
    • Administered orally, intramuscularly, or subcutaneously
  • The amendment also authorizes qualified technicians and interns to administer COVID-19 therapeutics
  • Individuals who will be ordering and/or administering COVID-19 therapeutics must:
    • Maintain current CPR certification
    • Complete ACPE-approved trainingĀ which includes:
      • Hands-on injection technique,
      • Clinical evaluation of indications and contraindications of COVID-19 therapeutics,
      • Recognition and treatment of emergency reactions to COVID-19 therapeutics, and
      • Any other training required by the FDA.
  • Training programsĀ which are known to the Board at this time (note this may not be all-inclusive and does not imply Board endorsement):
  • Pharmacists are required to be readily and immediately available to technicians when administering COVID-19 therapeutics
  • Pharmacies must retain records of the order/administration of COVID-19 therapeutics andĀ report the administrationĀ to:
  • Pharmacies which intend to order/administer COVID-19 therapeuticsĀ (pursuant to the HHS PREP Act or by Board-approved SWP, if available) shall:
Back to top